NEW YORK (GenomeWeb News) – The rate of growth at which drug makers invest in life science tools and technologies may never reach the levels seen during the 2000 or 2001 “boom,” according to Bruker BioSciences CEO Frank Laukien.
 
“It’s certainly better than it has been [recently] but may never again be at the 2000-2001 levels,” Laukien said during a break-out session following his presentation at the UBS Life Sciences Conference here today.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.